Patent ID: 8912177

Claim:
A method of treating polycystic kidney disease in a subject having polycystic kidney disease, comprising administering to the subject an effective amount of a compound represented by the following structural formula: or a pharmaceutically acceptable salt thereof, wherein R 1 is a phenyl group optionally and independently substituted with one or more substituents selected from the group consisting of —OR 30 , alkyl, and —O—[CH 2 ] p —O—; each R 30 is independently i) hydrogen; ii) a phenyl group optionally substituted with one or more substituents selected from the group consisting of halogen, C1-C6 alkyl, amino, C1-C6 alkylamino, C1-C6 dialkylamino, C1-C6 alkoxy, nitro, cyano, hydroxy, C1-C6 haloalkoxy, C1-C6 alkoxycarbonyl, C1-C6 alkylcarbonyl and C1-C6 haloalkyl; or iii) a C1-C10 alkyl group optionally substituted with one or more substituents selected from the group consisting of halogen, amino, C1-C6 alkylamino, C1-C6 dialkylamino, C1-C6 alkoxy, nitro, cyano, hydroxy, C1-C6 haloalkoxy, C1-C6 alkoxycarbonyl, C1-C6 alkylcarbonyl and C1-C6 haloalkyl; each p is independently 1, 2, 3 or 4; —N(R 2 R 3 ) is a pyrrolidinyl group optionally substituted with one or more substituents selected from the group consisting of halogen, C1-C5 alkyl, C1-C5 haloalkyl, hydroxyl, C1-C5 alkoxy, nitro, cyano, C1-C5 alkoxycarbonyl, C1-C5 alkylcarbonyl, C1-C5 haloalkoxy, amino, C1-C5 alkylamino and C1-C5 dialkylamino; R 4 is C6-C8 alkyl; and Y is —H.